Why FDA Instability is Driving Biotech Capital Abroad — What Investors Are Saying
FDA instability is reshaping biotech investment decisions in real time. Investors are recalibrating risk, pulling back, and even shifting capital abroad.
In case you missed it: We are bringing one of our most critical recent conversations to unpack how regulatory uncertainty is shifting the future of medicine. FDA instability is reshaping biotech investment decisions in real time. Across the board, investors are recalibrating risk, pulling back on funding, and even shifting capital abroad.
In this episode of the Making Medicine Podcast, John Stanford is joined by Rachel Sher of Manatt Health…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.